Funded through Gavi’s First Response Fund, a new financial mechanism created in June 2024 to make cash rapidly available to purchase vaccines in health emergencies, this deal guarantees the availability of these doses throughout 2024. 

The vaccines, marketed as JYNNEOS or IMVANEX, are set to support countries affected by the ongoing mpox outbreak.

The MVA-BN vaccine received prequalification from the WHO on September 13, and Bavarian Nordic will be ready to supply the vaccines pending the signing of a supply agreement with UNICEF, Gavi’s alliance partner, which will be delivering these doses.

“The First Response Fund was designed in collaboration with Gavi donors and partners specifically to provide rapid early funding for emergencies such as mpox. Using it today to fund the first direct transaction for vaccines in support of equitable access and the global response, just over a month since mpox was declared a public health emergency, takes us a long way towards our goal of protecting those most at risk,” said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. 

“We are committed to working with affected governments and our partners to turn these vaccines into vaccinations as quickly and effectively as possible and, over time, to build a global vaccine stockpile if sufficient funding is secured for Gavi’s work through 2030. We thank our donors for enabling us to act rapidly by committing funds to the First Response Fund before an emergency occurred.”

Paul Chaplin, president & CEO of Bavarian Nordic, said: “We are pleased to sign this agreement and strengthen our commitment to support Gavi and other global health partners, who have demonstrated strong leadership in making life-saving vaccines available for the vulnerable populations in developing countries for decades.

“The doses secured through this agreement will significantly increase the availability of mpox vaccines for African countries, and we are pleased that Gavi has selected our MVA-BN vaccine, which has proven highly effective during the global mpox outbreak in 2022.”

In addition to activating the First Response Fund, approved by the Gavi Board in June, Gavi moved rapidly to trigger the mechanism following the declaration of mpox as a public health emergency and unlocked emergency funding for affected countries to begin preparations for vaccine rollout, such as training of healthcare workers and community engagement and is working with donors and partners to help facilitate dose donations. 

Medium- and longer-term measures in place that are expected to be supportive of the mpox response include authorisation from Gavi’s Board, contingent on donor funding for Gavi’s next strategic period, to establish a stockpile of mpox vaccines for use in future outbreaks.

It also comes with an even longer horizon to contribute to the establishment of a sustainable vaccine manufacturing industry in Africa through the African Vaccine Manufacturing Accelerator, which was also launched in June.

This APA follows the delivery into the DRC of over a quarter of a million doses of Bavarian Nordic vaccines donated by other nations and Bavarian Nordic. The doses will be allocated to those most in need as per WHO’s Access and Allocation Mechanism, published on September 13.

Gavi, the Vaccine Alliance announced today the appointment of Dr Sania Nishtar as its new Chief Executive Officer.

Dr Nishtar, currently serving as a Senator in her home country of Pakistan, will assume the role on 18 March 2024.

Training and Career

A trained medical doctor, Dr Sania Nishtar has built an outstanding career over 30 years as a global public health leader.

In national government, she served between 2018 and 2022 as Special Assistant to the Prime Minister on Social Protection and Poverty Alleviation, a role with the status of a Federal Minister.

In 2013, during Pakistan’s Caretaker Government, she served as a Federal Minister with responsibility for re-establishing the country’s Ministry of Health among other roles, winning acclaim for transparency and accountability during her time in office.

During her career, Dr Nishtar has fulfilled several leadership positions in civil society and international organisations. She founded the non-profit NGO think tank Heartfile, which campaigns for health reform in Pakistan.

She was the inaugural Chair of the UN Secretary-General’s Independent Accountability Panel (IAP) for women’s and children’s health and Co-Chair of the WHO Independent High-level Commission on Noncommunicable Diseases, among many other roles.

Dr Nishtar served as Chair of Gavi’s Evaluation Advisory Committee from 2011 to 2014, and in 2016 served as an independent member of Gavi’s Board.

A prolific thought leader, she has co-authored dozens of academic papers and books, and has been published in many leading national and international newspapers. Dr Nishtar graduated from medical school as the best graduate in 1986.

She is a Fellow of the Royal College of Physicians and received a PhD from King’s College London, which awarded her an honorary Doctorate in Science, Honoris Causa, in 2019.

She is listed among the notable alumni of King’s College and in 2020 was among the BBC’s 100 Women, a list of inspiring and influential women from around the world.

Comments

Professor José Manuel Barroso, Chair of the Gavi Board, said:

“Over three decades of leadership at the national and global levels, Dr Nishtar has built a reputation as a tireless advocate for health equity, an innovative thinker and a proven doer when it comes to solving complex challenges. I am impressed by her accomplishments and excited by the possibilities her appointment brings for our Alliance and our ambitions to protect future generations. I also thank David Marlow for his effective leadership as Gavi’s CEO ad interim. His unfailing commitment to keep Gavi moving forward, by leading important structural and cultural reforms, has ensured Gavi is in the best possible shape to meet its current and future goals.”

Commenting on her appointment, Dr Sania Nishtar said:

“Health starts with life-saving vaccines. Over the past 23 years, Gavi has been one of the most impactful organisations in global health. The task ahead is enormous – from health impacts of climate change, to the need to tackle vaccine inequity, prepare for future outbreaks and boost routine immunisation, which I believe is the gateway to achieving Universal Health Coverage. I am honoured by the trust the Gavi Board has placed in me and look forward to working with Gavi’s talented staff and skilled Alliance partners to ensure Gavi reaches hundreds of millions of children in lower-income countries with life-saving vaccines against deadly and debilitating diseases.”

David Marlow, Gavi’s CEO ad interim, commented on Dr Nishtar’s appointment:

“I have been honoured to lead Gavi with the senior leadership team during this interim period and congratulate the Board on attracting and securing Dr Sania Nishtar as our next CEO. Together with the Gavi team, I am very much looking forward to working closely with Dr Nishtar and our Alliance partners as we strive to meet our ambitious goals.”

Dr Nishtar’s appointment comes at an important time for Gavi. With its fifth five-year strategic period drawing to a close at the end of 2025, Gavi will seek Board approval during 2024 for its 2026–2030 strategy.

Alongside future strategy, fundraising will be a priority for Dr Nishtar, with plans already in place for a high-level event to launch Gavi’s investment opportunity, to be co-hosted by France and Africa CDC in June.